CeriBell (CBLL) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $17.2 million, up 48% year-over-year, driven by new account expansion and increased product utilization.

• Gross margin improved to 87% from 84% in Q3 2023, reflecting operational efficiency.

• Net loss widened to $10.4 million ($1.85/share) from $7.1 million ($1.32/share) in Q3 2023, due to higher operating expenses as the company scales.

• Completed IPO in October 2024, raising $188–$188.2 million in net proceeds to fund growth initiatives.

• Ended Q3 with 504 active accounts and published clinical results showing improved ICU outcomes, including a four-day reduction in ICU stay and 33% lower risk of significant disability.

Financial highlights

• Product revenue grew 52% year-over-year to $13.3 million; subscription revenue rose 36% to $3.9 million.

• Gross profit was $15.0 million, up from $9.7 million in Q3 2023.

• Operating expenses increased 48% to $24.9 million, driven by commercial expansion and public company costs.

• Net loss per share for Q3 2024 was $(1.85), compared to $(1.32) in Q3 2023.

• Cash and cash equivalents at quarter-end were $14.1 million, excluding IPO proceeds.

Outlook and guidance

• Full-year 2024 revenue expected between $64.2–$64.7 million, representing 42–43% annual growth.

• Sequential Q4 revenue growth anticipated, with some seasonality and timing of large orders.

• Strategic decision to defer new account launches after mid-December to maximize long-term utilization.

• IPO proceeds position the company to invest in growth and achieve cash flow break-even; management expects continued losses as investments increase.

• Existing cash, IPO proceeds, and expected revenue are believed sufficient to fund operations for at least 12 months.